第一医药
(600833)
| 流通市值：28.24亿 | | | 总市值：28.24亿 |
| 流通股本：2.23亿 | | | 总股本：2.23亿 |
| 报告期 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 1,368,880,300.43 | 893,171,191.53 | 462,073,365.11 | 1,819,516,165.79 |
| 营业收入 | 1,368,880,300.43 | 893,171,191.53 | 462,073,365.11 | 1,819,516,165.79 |
| 二、营业总成本 | 1,367,026,359.88 | 891,988,686.49 | 456,313,443.95 | 1,791,998,507.54 |
| 营业成本 | 1,140,076,016.83 | 743,347,007.66 | 380,945,584.18 | 1,471,961,833.61 |
| 税金及附加 | 4,125,527.36 | 2,389,071.35 | 1,037,228.95 | 8,358,562.16 |
| 销售费用 | 191,832,654.92 | 126,660,847.22 | 61,851,195.31 | 239,312,154.08 |
| 管理费用 | 41,681,103.09 | 26,805,293.97 | 13,928,754.87 | 77,920,239.4 |
| 财务费用 | -10,688,942.32 | -7,213,533.71 | -1,449,319.36 | -5,554,281.71 |
| 其中:利息费用 | 4,510,224.26 | 2,935,074.3 | 1,107,602.6 | 7,588,182.55 |
| 其中:利息收入 | 17,145,957 | 11,697,296.47 | 3,260,657.52 | 13,583,712.24 |
| 加:公允价值变动收益 | - | - | - | 12,137,397.26 |
| 加:投资收益 | 10,739,697.33 | 8,795,169.67 | 1,079,042.43 | 11,726,371.2 |
| 资产处置收益 | 140,908,008.63 | 140,050,836.52 | 1,019,871.87 | 65,128,680.61 |
| 资产减值损失(新) | - | - | - | -5,650,044.12 |
| 信用减值损失(新) | -270,036 | -270,036 | - | -12,360,247.13 |
| 其他收益 | 415,914.24 | 281,735.09 | 183,192.18 | 454,413.56 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 153,647,524.75 | 150,040,210.32 | 8,042,027.64 | 98,954,229.63 |
| 加:营业外收入 | 41,208,224.81 | 21,310,491.1 | 40,299,849.51 | 19,881,711.35 |
| 减:营业外支出 | 884,283.12 | 758,716.83 | 436,986.94 | 1,325,249.56 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 193,971,466.44 | 170,591,984.59 | 47,904,890.21 | 117,510,691.42 |
| 减:所得税费用 | 46,613,373.74 | 40,877,261.81 | 11,851,054.19 | 28,235,457.42 |
| 六、净利润 | 147,358,092.7 | 129,714,722.78 | 36,053,836.02 | 89,275,234 |
| 持续经营净利润 | 147,358,092.7 | 129,714,722.78 | 36,053,836.02 | 89,275,234 |
| 归属于母公司股东的净利润 | 147,324,925.33 | 129,789,131.26 | 36,053,836.02 | 89,275,234 |
| 少数股东损益 | 33,167.37 | -74,408.48 | - | - |
| (一)基本每股收益 | 0.66 | 0.58 | 0.16 | 0.4 |
| (二)稀释每股收益 | 0.66 | 0.58 | 0.16 | 0.4 |
| 八、其他综合收益 | -698,050.74 | -19,500,998.78 | 961,573.32 | 4,001,955.91 |
| 归属于母公司股东的其他综合收益 | -698,050.74 | -19,500,998.78 | 961,573.32 | 4,001,955.91 |
| 九、综合收益总额 | 146,660,041.96 | 110,213,724 | 37,015,409.34 | 93,277,189.91 |
| 归属于母公司股东的综合收益总额 | 146,626,874.59 | 110,288,132.48 | 37,015,409.34 | 93,277,189.91 |
| 归属于少数股东的综合收益总额 | 33,167.37 | -74,408.48 | - | - |
| 公告日期 | 2024-10-31 | 2024-08-31 | 2024-04-30 | 2024-03-30 |
| 审计意见(境内) | | | | 标准无保留意见 |